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Hereditary optic neuropathies are diseases affecting the optic nerve. The most com-
mon are mitochondrial hereditary optic neuropathies, i.e., the maternally inherited Leber’s
hereditary optic neuropathy (LHON) and dominant optic atrophy (DOA). They both share
a mitochondrial pathogenesis that leads to the selective loss of retinal ganglion cells
and axons, in particular of the papillo-macular bundle. Typically, LHON is characterized by
an acute/subacute loss of central vision associated with impairment of color vision and
swelling of retinal nerve fibers followed by optic atrophy. DOA, instead, is characterized by
a childhood-onset and slowly progressive loss of central vision, worsening over the years,
leading to optic atrophy. The diagnostic workup includes neuro-ophthalmologic evaluation
and genetic testing of the three most common mitochondrial DNA mutations affecting com-
plex I (11778/ND4, 3460/ND1, and 14484/ND6) for LHON and sequencing of the nuclear
gene OPA1 for DOA.Therapeutic strategies are still limited including agents that bypass the
complex I defect and exert an antioxidant effect (idebenone). Further strategies are aimed
at stimulating compensatory mitochondrial biogenesis. Gene therapy is also a promising
avenue that still needs to be validated.
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INTRODUCTION
Hereditary optic neuropathies are a heterogeneous group of dis-
eases, which may be either an isolated optic neuropathy or optic
neuropathy in the context of a more complex multi-systemic
disease. The estimated minimum prevalence of hereditary optic
neuropathies is about 1 in 10,000 (1).
Optic neuropathy, as part of a more complex spectrum of clin-
ical symptoms, is common in hereditary neurodegenerative disor-
ders with evidence of mitochondrial dysfunction [for a review
see Ref. (2)] such as OPA1 “plus” syndrome (3), mitochondr-
ial encephalomyopathy lactic acidosis and stroke-like syndrome
(MELAS) (4), LHON/dystonia/MELAS/Leigh overlapping syn-
drome (5, 6), myoclonic epilepsy with ragged red fibers (MERRF)
(7), POLG1-related syndrome (8), Friedreich ataxia (9), Charcot–
Marie Tooth type 2A (10), Mohr–Tranebjerg syndrome (11), SPG7
syndrome (12), Wolfram syndrome (13), spinocerebellar ataxias
(14), and DNMT1-related disorders (15).
The main non-syndromic hereditary optic neuropathies are
Leber’s hereditary optic neuropathy (LHON) and dominant optic
atrophy (DOA) and both are primary mitochondrial hereditary
optic neuropathies (16). Other rare recessive or X-linked forms of
optic neuropathy are also described, in most cases not yet resolved
from the genetic point of view.
GENETIC BASIS OF ISOLATED OPTIC NEUROPATHIES
Leber’s hereditary optic neuropathy is a maternally inherited
disorder and in 90–95% of cases it is due to one of three
mitochondrial DNA (mtDNA) mutations (11778/ND4, 3460/
ND1, and 14484/ND6) (17). Other rare mtDNA mutations have
been reported in association with LHON (18). These rare muta-
tions may need testing for, by complete sequence of mtDNA, if the
clinical suspicion of LHON is high and a maternal inheritance is
obvious.
Dominant optic atrophy, in about 70% of cases, is due to muta-
tions in the OPA1 gene. Three other loci have been associated with
autosomal DOA and designated as OPA4 (19), OPA5 (20), and
OPA8 (21). Furthermore, heterozygous mutations in the OPA3
gene have been associated with DOA and cataract (22), as well
as heterozygous mutations in the WSF1 gene have been reported
in association with DOA and hearing loss (23). Both OPA3 and
WSF1 genes are mostly associated with recessive mutations leading
to Costeff (24) and Wolfram syndromes, respectively. Additional
loci have been identified in X-linked (OPA2) (25) and reces-
sive (OPA6 and OPA7 ) hereditary optic neuropathies, the latter
recently associated with mutations in TMEM126A (26, 27).
The next sections will focus on LHON and DOA, the most fre-
quent and prototypical hereditary optic neuropathies, for which
an extensive body of studies is available.
CLINICAL PRESENTATION OF LHON/DOA AND CLINICAL
WORKUP
Leber’s hereditary optic neuropathy typically affects young adult
males presenting with unilateral or bilateral subacute/acute pain-
less loss of central vision. The clinical course typically involves a
rapid worsening of visual acuity over a few weeks (nadir reached
in about one to 6 months) and subsequent stabilization of visual
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loss, entering the chronic phase. Loss of vision can be very severe
leading to legal blindness in most cases (17). In the acute phase,
there is bilateral sequential vision loss, significant impairment of
color vision, and usually maintenance of the pupillary light reflex.
Fundus examination shows, in the acute phase, pseudoedema of
the optic disk and retinal nerve fibers initially involving mainly
the inferior and superior arcades with teleangectias (Figure 1A)
and temporal or diffuse optic disk pallor in later stage of the dis-
ease. Visual fields reveal central or cecocentral scotoma, which
progressively worsens over time (28). Optical coherence tomogra-
phy (OCT) demonstrates an initial thickening of the temporal and
inferior peripapillary fibers, which is followed by the thickening of
the superior and, lastly, of the nasal fibers (Figure 1A). The tempo-
ral fibers are lost first and the nasal fibers are the most spared (29).
Fluorescein angiography in the acute phase usually fails to show
leakage of fluorescein (hence pseudo disk edema) and this is a
useful marker for differentiating LHON from inflammatory optic
neuropathies with true disk edema that causes fluorescein leakage
(28). Another useful clinical sign, which distinguishes LHON from
optic neuritis (the most important clinical differential diagnosis
for LHON) is the usual absence of a relative afferent pupillary
defect. The maintenance of the pupillary light response is partly
due to the bilateral symmetry of the disease process and partly to
the relative sparing of melanopsin retinal ganglion cells (mRGCs)
in LHON, as revealed by post-mortem investigations (30). These
cells are about 1% of the total RGCs and they contribute mainly
to circadian photo-entrainment, but through the retinal projec-
tions to the olivary pretectal nucleus (OPN), they also regulate
FIGURE 1 | (A) Fundus and OCT in the acute-phase of LHON. Fundus exam
shows moderate swelling of the retinal nerve fibers mainly involving the
superior and inferior arcades around the optic disk associated with loss of
fibers in the papillo-macular bundle (temporal pallor), retinal vessels tortuosity,
and telangiectasias. Optical coherence tomography (OCT) shows retinal nerve
fiber layer thinning of the temporal quadrant with thickening of all the other
quadrants. (B) Fundus and OCT of a LHON carrier. Fundus examination
reveals mild swelling of the superior and inferior retinal nerve fibers and
microangiopathy. OCT demonstrates retinal nerve fiber layer thickening more
evident in the supero-nasal (OD) and supero-inferior (OS) quadrants.
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the pupillary light reflex. Clinical studies demonstrated the main-
tenance of the pupil responses in LHON patients (31, 32). The
diagnostic workup in LHON also may include other neurophys-
iologic tests such as visual evoked potentials (VEPs) that reveal
delayed latency and reduced amplitude of cortical responses and
pattern electroretinograms (PERGs), which demonstrate reduced
amplitude and delayed latency of responses (33).
Some LHON patients may spontaneously recover vision during
the clinical course (34). The rate of spontaneous recovery is vari-
able for the three LHON mutations being 4–20% for 11778/ND4
and 3460/ND1 mutation, and 50% or more for the 14484/ND6
(34, 35). This recovery may occur after the nadir of the disease at
about 6–8 months and up to 5 years after the onset (1).
The family history is very helpful since it often reveals the pres-
ence of other affected individuals along the maternal lineage, in
prevalence males.
Leber’s hereditary optic neuropathy is due in the large majority
of cases (90–95%) to the three classical LHON mutations, which
are homoplasmic (i.e., all the mtDNA copies harbor the mutation)
in most of the families. Despite the genetic risk of disease seems
to be equal among all individuals along the maternal lineage, the
penetrance is incomplete and the disease affects prevalently males
(17). Genetic counseling implies in these patients that the off-
spring of a woman carrying the LHON mutation will harbor the
mutation, whereas offspring of males are spared. The probability
to become affected is roughly 10% in women and 50% in men
carrying the 11778/ND4 LHON mutation (17). The reason for the
lower penetrance in females is possibly related to the protective
role exerted by estrogens on cellular metabolism (36). The risk of
recurrence for individuals younger than 50 years of age and mater-
nally related to the index case has been calculated by Harding and
colleagues (37). A specific mtDNA background, haplogroup J, due
to recurrence of non-synonymous variants affecting complex I
and III subunit genes, has been associated with higher penetrance
of the mutations 11778/ND4 and 14484/ND6 (38).
Other known environmental risk factors for LHON are smok-
ing, alcohol, and the use of some antibiotics (i.e., macrolids,
aminoglicosides, ethambutol, isoniazide, and linezolid) (39, 40).
Clinical counseling should include avoiding these risk factors.
Though usually LHON presents as an isolated optic neuropa-
thy, in a few cases, there may be the coexistence of additional
signs and symptoms, such as myoclonus,MS-like features, epilepsy,
heart conduction defects, peripheral neuropathy, dystonia, and
myopathy (41).
Other ancillary tests that have been shown useful to complete
the clinical characterization of LHON patients include brain and
muscle magnetic resonance spectroscopy (42, 43) and lactic acid
after standardized exercise (44).
Asymptomatic carriers of LHON mutation may also have
swollen retinal nerve fibers that can be seen on fundus exami-
nation and by OCT (45, 46) (Figure 1B), abnormalities in color
vision (47), and in neural conduction along the visual pathways
(33, 48).
Dominant optic atrophy usually affects both males and females
in young childhood, and in the large majority of cases, is due
to mutations in the OPA1 gene (49, 50). There is incomplete
penetrance and the classical clinical picture of DOA differs from
LHON in that the former presents as a slowly progressive loss
of vision with a smaller central or cecocentral scotoma (51).
The clinical severity is very variable even within the same pedi-
gree (52). As in LHON, OCT demonstrates preferential involve-
ment of the papillo-macular bundle with a corresponding loss
of fibers in the temporal sector of the optic disk and relative
sparing of the nasal quadrant (53), which leads to temporal or
diffuse optic atrophy. The main differential diagnosis for DOA
is normal tension glaucoma, due to the frequent cupping of
chronic DOA cases (54). Interestingly, OCT also demonstrates
that optic disk size is reduced in DOA compared to controls
and this might be explained by the role played by OPA1 in reg-
ulating developmental apoptosis and shaping optic nerve head
morphology (55).
As for LHON, the clinical examination in DOA demonstrates
the maintenance of the pupillary light reflex. This finding is cor-
roborated by histological studies showing a relative sparing of
mRGCs in DOA as well (30, 56).
VEPs may be normal or disclose a delayed latency and reduced
amplitude of cortical responses (57).
Genetic counseling for DOA implies the rules of Mendelian
autosomal dominant diseases and so the probability that offspring
of an affected individual will inherit the mutation is 50% and this is
equal for males and females. Prenatal genetic diagnosis is feasible,
as well as pre-implantation diagnosis, thus providing the option
to avoid transmission of the mutant OPA1 allele to offspring of
an affected parent. As for LHON, DOA also may present a “plus”
phenotype, which includes deafness, chronic external ophthalmo-
plegia, peripheral neuropathy, cerebellar atrophy, and mitochon-
drial myopathy (3, 58). In these cases, muscle biopsy histology
and histoenzymology may disclose the hallmarks of mitochondr-
ial myopathy with cytochrome c oxidase negative fibers, whereas
molecular analysis will reveal the pathological accumulation of
multiple mtDNA deletions (58). Moreover, these patients often
present increased lactic acid levels after standardized exercise.
The OPA1 mutations associated with the “plus” phenotype are
in most cases missense mutations affecting the GTP-ase domain
of the OPA1 protein (58), as opposed to the majority of mutations
associated with non-syndromic DOA, mostly predicted to induce
haploinsufficiency.
FOLLOW-UP MANAGEMENT
Patients with hereditary optic neuropathies should be fol-
lowed regularly during the disease course, particularly in the
acute/subacute phase. The most important exams for the clini-
cal follow-up of these patients are color vision, visual fields, visual
acuity, and OCT.
Visual acuity is usually poor in LHON and some patients may
end with bare light perception. DOA patients present a more vari-
able clinical severity (52). Visual fields usually deteriorate from
small to very large central scotoma in LHON and may remain
small and stable in DOA over long periods of time (59). In LHON,
visual fields may sometimes show reduction in size of the sco-
toma or its fenestration (60), both leading to an improvement in
visual acuity (Figure 2). However, spontaneous visual recovery has
never been described in DOA (61). Only one rare OPA1 mutation
has been associated with a reversible LHON-like visual loss (62).
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FIGURE 2 | 30° and 10° visual field pattern of recovery in LHON.
(A) Example of scotoma fenestration (OS) in a LHON patient carrying the
14484/ND6 mutation (B) Example of scotoma contraction (OS) in a LHON
patient carrying the 11778/ND4 mutation and (C) Example of both scotoma
fenestration and contraction (OD) in a LHON patient carrying the
11778/ND4 mutation.
A component of the visual improvement in LHON can be the
adaptive phenomenon of eccentric fixation (63).
CLINICAL SIGNIFICANCE
Although diseases as LHON and DOA are rare, they constitute a
terrible tragedy for the patients who go blind and for their families.
Unlike most common causes of blindness, these hereditary optic
neuropathies are not associated with old age. Generally, patients
with LHON and DOA loose their vision before young adulthood
and the disease tend to be bilaterally symmetrical. Hence, typical
patients will loose their vision as a teenager or in their 20s and face
a lifetime of blindness and disability. Parents and siblings are often
part of the process of diagnosis and management.
THERAPEUTIC OPTIONS
Therapeutic options for hereditary optic neuropathies are still
limited (64) and up to now only one randomized double-blind
placebo-controlled study with idebenone in LHON has been
concluded (65).
Idebenone (a quinone analog of coenzyme Q10) has been
reported to be effective in increasing the rate of recovery in LHON
especially in patients with discordant visual acuity and if the
patients are treated early in the disease course and for a long time
(35, 65). These findings may suggest that there is a specific win-
dow of opportunity for increasing the rate of visual recovery with
idebenone treatment. Coenzyme Q10 and idebenone are able to
bypass the complex I defect caused by the LHON mutation and
permit the transfer of electrons from NADH directly to complex III
(66). A new double-blind placebo-controlled trial with idebenone
in LHON is about to start with a longer follow-up and different
design predefined primary end-points and dosages (Yu-Wai-Man,
personal communication). Idebenone treatment has also been
reported to ameliorate color vision in LHON (67).
Very preliminarily, encouraging results with idebenone treat-
ment have been also reported in DOA patients (61) for whom
spontaneous recovery has not been previously described. The
rationale for the use of idebenone in DOA is that also in
OPA1-related DOA, there is a complex I defect as in LHON (68).
More recently, other drugs are under investigations, such as
the novel quinone molecule, alfa-tocotrienol EPI-743, which has
shown promising results in an open-label trial on a limited group
of LHON patients (69). These results need to be confirmed in
larger controlled trial.
Other therapeutic strategies for LHON may include the use
of drugs that might stimulate mitochondrial biogenesis, which
has been demonstrated as a possible compensatory mechanism
for LHON and other mitochondrial disorders (70). These include
bezafibrate and rosiglitazone and novel molecules such as resver-
atrol and AICAR (5-aminoimidazole-4-carboxamide ribonucleo-
side) (71).
For a variety of reasons, gene therapy is a promising avenue
for LHON treatment. The eye is easily accessible and provides a
privileged space into which inject a viral vector. The most studied
approach in LHON has been the AAV-mediated nuclear allotopic
expression of mtDNA-encoded genes delivered to mitochondria
(72, 73). This approach has been used in mouse models of LHON
by the intravitreal delivery of an AAV vector carrying the wild-
type ND4 (74, 75). This approach is now starting to be applied
in LHON patients. However, it remains somehow controversial in
terms of feasibility and efficiency (76). Other strategies include
the direct delivery within mitochondria of the whole mtDNA or
of an AAV vector containing the mtDNA-encoded ND4 subunit
gene (77). These approaches are extremely promising but need to
be validated.
For DOA, being a nuclear-encoded disease, gene therapy strat-
egy should be more straightforward and feasible, as demonstrated
by the recent encouraging results obtained with the gene ther-
apy in Leber’s congenital amaurosis (78, 79). A proof of principle
that genetically determined RGCs loss can be rescued by an AAV-
based strategy with intravitreal delivery of the viral vector has
been provided in an AIF mouse model, the so-called Harlequine
mouse (80). There is issue of packaging, the 30 exons of the OPA1
gene into the AAV. Another problem to solve is which isoform
of the OPA1 gene should be used as the most efficient to res-
cue the phenotype in RGCs. Currently, the specific role played by
the eight OPA1 isoforms has not yet been systematically investi-
gated. Another critical point is that the delivery of wild-type OPA1
to RGCs would likely complement haploinsufficiency mutations
but more investigations are needed on the purported dominant
negative mechanism of missense mutations. Nonetheless, gene
therapy in DOA is a realistic objective, which will be pursued
in the next future, providing some hope for treatment of DOA
patients.
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